New approaches to antigen delivery

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 17, Issue 3, 2000, Pages 165-248

  FitzGerald, David ^a   Mrsny, Randall J ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENENTECH INC   (United States)

Author keywords

Antigen delivery; Mucosal immunity; Tolerization; Vaccination

Indexed keywords

ANTHRAX TOXIN; ANTIGEN; BACTERIAL TOXIN; CANCER VACCINE; CHOLERA TOXIN; DNA VACCINE; DRUG CARRIER; ESCHERICHIA COLI ENTEROTOXIN; IMMUNOLIPOSOME; IMMUNOLOGICAL ADJUVANT; POLYMER; PSEUDOMONAS EXOTOXIN; SHIGA TOXIN; VACCINE; VIRUS VECTOR;

ANTIGEN PRESENTING CELL; BIOTECHNOLOGY; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; TH1 CELL; TH2 CELL; VACCINE PRODUCTION;

EID: 0033916235     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/critrevtherdrugcarriersyst.v17.i3.10     Document Type: Review

References (447)

1. Carmeli, Y., Troillet, N., Karchmer, A.W., and Samore, M.H., Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa, Arch. Internal Med., 159(10), 1127, 1999.
2. Coninx, R., Mathieu, C., Debacker, M., Mirzoev, F., Ismaelov, A., de Haller, R., and Meddings, D.R., First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons, Lancet, 353(9157), 969, 1999.
3. Austin, D.J., Bonten, M.J., Weinstein, R.A., Slaughter, S., and Andersen, R.M., Vancomycin-resistant enterococci in intensive-care hospital settings: Transmission dynamics, persistance, and the impact of infection control programs, Proc. Natl. Acad. Sci. USA, 96(12), 6908, 1999.
4. Huycke, M.M., Sahm, D.F., and Gilmore, M.S., Multiple-drug resistant enterococci: The nature of the problem and an agenda for the future, Emerg. Infect. Dis., 4(2), 239, 1998.
5. van den Braak, N., van Belkum, A., van Keulen, M., Vliegenthart, J., Verbrugh, H.A., and Endtz, H.P., Molecular characterization of vancomycin-resistant enterocci from hospitalized patients and poultry products in the Netherlands, J. Clin. Microbiol., 36(7), 1927, 1998.
6. Novack, R., Henriques, B., Charpentier, E., Normark, S., and Toumanen, E., Emergence of vancomycin tolerance in Streptococcus pneumoniæ, Nature, 399(6736), 590, 1999.
7. Song, J.-H., Lee, N.Y., Ichiyama, S., Yoshida, R., Hirakata, Y., Fu, W., Chongthaleong, A., Aswapokee, N., Chiu, C.H., Lalitha, M.K., Thomas, K., Perera, J., Yee, T.T., Jamal, F., Warsa, U.C., Vihn, B.X., Jacobs, M.R., Appelbaum, P.C., and Pai, C.H., Spread of drug-resistant Streptococcus pneumoniæ in Asian countries: Asian network for surveillance of resistant pathogens (ANSORP) study, Clin. Infect. Dis., 28(6), 1206, 1999.
8. Barrett, J.F. and Hoch, J.A., Two-component signal transduction as a target for microbial anti-infective therapy, Antimicrob. Agents Chemother., 42(7), 1529, 1998.
9. Threlfall, E.J., Ward, L.R., Skinner, J.A., and Rowe, B., Increase in multiple antibiotic resistance in nontyphoidal salmonellas from humans in England and Wales: A comparison of data for 1994 and 1996, Microbiol. Drug Resist., 3(3), 263, 1997.
10. Anderson, R.M., The pandemic of antibiotic resistance, Nat. Medicine, 5(2), 147, 1999.
11. Hazuda, D. and Kuo, L., Failure of AZT: A molecular perspective, Nat. Medicine, 3(8), 836, 1997.
12. Karpas, A., Ash, S., and Bainbridge, D., Are anti-HIV drugs an effective treatment?, Nat. Medicine, 3(10), 1052, 1997.
13. McClean, A.R., Vaccines and their impact on the control of disease, Br. Med. Bull., 54(3), 545, 1998.
14. Hilleman, M.R., Six decades of vaccine development - A personal history, Nat. Medicine, 4(5), 507, 1998.
15. Sansonetti, P.J., Slaying the Hydra all at once or head by head?, Nat. Medicine, 4(5 Vaccine Suppl.), 499, 1998.
16. Cohen, D., Ashkenazi, S., Green, M., Gdalevich, M., Yavzori, M., Orr, N., Robin, G., Slepon, R., Lerman, Y., Block, C., Ashkenazi, I., Hale, L., Sadoff, J., Schneerson, R., Robbins, J., Weiner, M., and Shemer, J., Clinical trials of Shigella in Israel, Adv. Exp. Med. Biol., 397, 159, 1996.
17. Phalipon, A. and Sansonetti, P.J., Live attenuated Shigella flexneri mutants as vaccine candidates against shigellosis and vectors for antigen delivery, Biologicals, 23(2), 125, 1995.
18. Vesikari, T., Rotavirus vaccines: Development and use for the prevention of dirrhoreal disease, Ann. Med., 31(1), 79, 1999.
19. Konno, T., Suzuki, H., Kutsuzawa, T., Imai, A., Katsushima, N., Sakamoto, M., Kitaoka, S., and Tsuboi, R., Human rotovirus infection in infants and young children with intussusception, J. Med. Virol., 2(3), 265, 1978.
20. Mulcahy, D.L., Kamath, K.R., de Silva, L.M., Hodges, S., Carter, I.W., and Cloonan, M.J., A two-part study of the ætiological role of rotovirus in intussusception, J. Med. Virol., 9(1), 51, 1982.
21. Avery, R.K., Vaccination of the immunosuppressed adult patient with rheumatologic disease, Rheum. Dis. Clin. N. Amer., 25(3), 567, 1999.
22. Remarque, E.J., Influenza vaccination in elderly people, Exp. Gerontol., 34(3), 445, 1999.
23. Watson, J.C., Hadler, S.C., Dykewicz, C.A., Reef, S., and Phillips, L., Measles, mumps, and rubella - Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR - Morb. Mortal. Wkly. Rep., 47(RR-8), 1, 1998.
24. Brown, F., Foot-and-mouth disease and beyond: Vaccine design, past, present, and future, Arch. Virol. Suppl., 15, 179, 1999.
25. Liu, M.A., Vaccine developments, Nat. Medicine, 4(5), 515, 1998.
26. Powell, M.F., Newman, M.J., and Burdman, J.R., Eds., Vaccine Design: The Subunit and Adjuvant Approach, in Pharmaceutical Biotechnology, Vol. 6, New York: Plenum Press, 1995.
27. Loscher, T., Keystone, J.S., and Steffen, R., Vaccination of travelers against hepatitis A and B, J. Travel Med., 6(2), 107, 1999.
28. Raychaudhuri, S. and Rock, K.L., Fully mobilizing host defense: Building better vaccines, Nat. Biotech., 16(11), 1025, 1998.
29. Aichele, P., Kyburz, D., Ohashi, P.S., Odermatt, B., Zinkernagel, R.M., Hengartner, H., and Pircher, H., Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model, Proc. Natl. Acad. Sci. USA, 91(2), 444, 1994.
30. Coers, J., Monahan, C., and Roy, C.R., Modulation of phagosome biogenesis by Legionella pneumophila creates an organelle permissive for intracellular growth, Nat. Cell Biol., 1(7), 451, 1999.
31. Meresse, S., Steele Mortimer, O., Moreno, E., Desjardins, M., Finlay, B., and Gorvel, J.-P., Controlling the maturation of pathogen-containing vacuoles: A matter of life and death, Nat. Cell Biol., 1(7), E183, 1999.
32. Mestecky, J., Moloveanu, Z., Novak, M., Huang, W.-Q., Gilley, R.M., Staas, J.K., Schafer, D., and Compans, R.W., Biodegradable microspheres for the delivery of oral vaccines, J. Controlled Rel., 28, 131, 1994.
33. Kaufmann, S.H.E., Concepts in Vaccine Development, Berlin: Walter de Gruyter, 1996.
34. O'Hagan, D.T., Recent advances in vaccine adjuvants for systemic and mucosal administration, J. Pharrn. Pharmacol., 50, 1, 1998.
35. Dorner, F., Eibl, J., and Barrett, P.N., New technologies for vaccines, Weiner Klinische Wochenschrift, 111(5), 199, 1999.
36. Gradon, J.D. and Lutwick, L.I., Maintaining and enhancing vaccine immunogenicity, Infect. Dis. Clin. North Am., 13(1), 39, 1999.
37. Mahon, B.P., Moore, A., Johnson, P.A., and Mills, K.H., Approaches to new vaccines, Crit. Rev. Biotechnol., 18(4), 257, 1998.
38. Jaffe, C.L., Recent trends in vaccine development and immunization, Clin. Dermatol., 17(3), 339, 1999.
39. Freytag, L.C. and Clements, J.D., Bacterial toxins as mucosal adjuvants, Curr. Top. Microbiol. Immunol., 236, 215, 1999.
40. Feltquate, D.M., DNA vaccines: vector design, delivery, and antigen presentation, J. Cell Biochem. Suppl., 31, 304, 1998.
41. Kagnoff, M. and Kiyono, H., Essentials of Mucosal Immunity, Philadelphia, PA: Lippicott-William & Wilkins, 1996.
42. Ogra, P., Mestecky, J., Lamm, M., Strober, W., McGhee, J.R., and Bienenstock, J., Mucosal Immunology, San Diego, CA: Academic Press, 1998.
43. Palucka, K. and Banchereau, J., Linking innate and adaptive immunity, Nat. Medicine, 5(8), 868, 1999.
44. Dugas, B., Mercenier, A., Lenoir-Wijnkoop, I., Arnaud, C., Dugas, N., and Postaire, E., Immunity and probiotics, Trends Immunol., 20(9), 387, 1999.
45. Kraehenbuhl, J.-P. and Neutra, M.R., Molecular and cellular basis of immune protection of mucosal surfaces, Physiol. Rev., 72(4), 853, 1992.
46. Banchereau, J. and Steinman, R.M., Dendritic cells and the control of immunity, Nature, 392(6673), 245, 1998.
47. Sigal, L.J., Crotty, S., Andino, R., and Rock, K.L., Cytotoxic T-cell immunity to virus-infected non-hematopoietic cells requires presentation of exogenous antigen, Nature, 398(6722), 26, 1999.
48. Rock, K.L. and Goldberg, A.L., Degradation of cell proteins and the generation of MHC class I-presented peptides, Ann. Rev. Immunol., 17, 739, 1999.
49. Roitt, I., Male, D., and Brostoff, J., Immunology, Mosby Year Book, 1998.
50. Paul, W.E., Fundamental Immunology, Philadelphia, PA: Lippicott-William & Wilkins, 1998.
51. Janeway, C., Travers, P., Capra, J.D., and Walport, M.J., Immunobiology: The Immune System in Health and Disease, Walla Walla, WA: Garland, 1999.
52. Adams, S.E. and Kingsman, A.J., Retrovirus and retrotransposon particles as antigen presentation and delivery systems, Pharm. Biotechnol., 6, 769, 1995.
53. McDonald, T.T., T cell immunity to oral allergens, Curr. Opin. Immunol., 10(6), 620, 1998.
54. Ahlers, J.D., Dunlop, N., Alling, D.W., Nara, P.L., and Berzofsky, J.A., Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: Granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes, J. Immunol., 158(8), 3947, 1997.
55. Singh, M. and O'Hagan, D., Advances in vaccine adjuvants, Nat. Biotech., 17(11), 1075, 1999.
56. Abbas, A.K., Murphy, K.M., and Sher, A., Functional diversity of helper T lymphocytes, Nature, 383(6603), 787, 1996.
57. Stumbles, P.A., Thomas, J.A., Pimm, C.L., Lee, P.T., Venaille, T.J., Proksch, S., and Holt, P.G., Resting respiratory tract dendritic cells preferentially stimulate T helper cell type 2 (Th2) responses and require obligatory cytokine signals for induction of Th1 immunity, J. Exp. Med., 188(11), 2019, 1998.
58. Johansen, H.K., Cryz, Jr., S.J., Hougen, H.P., Moser, C., and Hoiby, N., Vaccination promotes Th1-like inflammation and survival in chronic Pseudomonas aeruginosa pneumonia: A new prophylatic principle, Behring. Inst. Mitt., 98, 269, 1997.
59. Hern, S.L. and White, J.L., Structure and properties of aluminum-containing adjuvants, in Vaccine Design: The Subunit and Adjuvant Approach, Vol. 6, 1st ed., Powell, M.F., Newman, M.J., and Burdman, J.R., Eds., New York: Plenum, 1995, 249.
60. Gallucci, S., Lolkema, M., and Matzinger, P., Natural adjuvants: Endogenous activators of dendritic cells, Nat. Medicine, 5(11), 1249, 1999.
61. + T cells to cause immunopathology, J. Exp. Med., 187(5), 763, 1998.
62. Underhill, D.M., Ozinsky, A., Hajjar, A.M., Stevens, A., Wilson, C.B., Bassetti, M., and Aderem, A., The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminate between pathogens, Nature, 401(6755), 811, 1999.
63. Rovere, P., Vallinoto, C., Bondanza, A., Crosti, M.C., Rescigno, M., Riccciardi-Castagnoli, P., Rugarli, C., and Manfredi, A.A., Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function, J. Immunol., 161(9), 4467, 1998.
64. Medzhitov, R. and Janeway, Jr., C.A., Innate immunity: The virtues of a nonclonal system of recognition, Cell, 91, 295, 1998.
65. Aichele, P., Bachmann, M.F., Hengartner, H., and Zinkernagel, R.M., Immunopathology or organ-specific autoimmunity as a consequence of virus infection, Immunol. Rev., 152, 21, 1996.
66. Xiao, B.-G. and Link, H., Is there a balance between microglia and astrocytes in regulating Th1/Th2 responses and neuropathologies?, Immunol. Today, 20(11), 477, 1999.
67. Cao, Q., Batey, R., Pang, G., Russell, A., and Clancy, R., IL-6, IFN-γ, and TNF-α production by liver-associated T cells and acute liver injury in rats administered concanavalin A, Immunol. Cell Biol., 76(6), 542, 1998.
68. Quayle, A.J., Pudney, J., Munoz, D.E., and Anderson, D.J., Characterization of T lymphocytes and antigen-presenting cell in the murine male urethra, Biol. Reprod., 51, 809, 1994.
69. Kaul, D. and Ogra, P.L., Mucosal responses to parenteral and mucosal vaccines, Develop. Biol. Standard., 95, 141, 1998.
70. Mestecky, J., Moldoveanu, Z., Novak, M., and Compans, R.W., Mucosal immunity and strategies for novel microbial vaccines, Acta Paediatr. Jpn., 36, 537, 1994.
71. Russell, M.W., Hedges, S.R., Wu, H.Y., Hook, 3rd, E.W., and Mestecky, J., Mucosal imunity in the genital tract: Prospects for vaccines against sexually transmitted diseases - A review, Am. J. Reprod. Immunol., 42(1), 58, 1999.
72. Tamura, S., Miyata, K., Matsuo, K., Asanuma, H., Takahashi, H., Nakajima, K., Suzuki, Y., Aizawa, C., and Kurata, T., Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein, J. Immunol., 156, 3892, 1996.
73. Staats, H.F., Montgomery, S.P., and Palker, T.J., Intranasal immunization is superior to vaginal, gastric, or rectal immunization for the induction of systemic and mucosal anti-HIV antibody responses, AIDS Res. Hum. Retroviruses, 13(11), 945, 1997.
74. Wu, H.-Y., Nikolova, E.B., Beagley, K.W., Eldridge, J.H., and Russell, M.W., Development of antibody-secreting cells and antigen-specific T cells in cervical lymph nodes after intranasal immunization, Infect. Immun., 65(1), 227, 1997.
75. VanCott, T.C., Kaminski, R.W., Mascola, J.R., Kalyanaraman, V.S., Wassef, N.M., Alving, C.R., Ulrich, J.T., Lowell, G.H., and Birx, D.L., HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160, J. Immunol, 160(4), 2000, 1998.
76. Joag, S.V., Liu, Z.Q., Stephens, E.B., Smith, M.S., Kumar, A., Li, Z., Wang, C., Sheffer, D., Jia, F., Foresman, L., Adany, I., Lifson, J., McClure, H.M., and Narayan, O., Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS, J. Virol., 72(11), 9069, 1998.
77. Johansen, H.K., Rask, C., Fredrikson, M., Eriksson, K., Czerkinsky, C., and Holmgren, J., Antibodies and antibody-secreting cells in the female genital tract after vaginal and intranasal immunization with cholera toxin B subunit or conjugates, Infect. Immun., 66(2), 514, 1998.
78. Xiang, Z. and Ertl, H.C., Induction of mucosal immunity with a replication-defective adenoviral recombinant, Vaccine, 17(15-16), 2003, 1999.
79. Xiang, Z.Q., Pasquini, S., and Ertl, H.C., Induction of genital immunity by priming by DNA and intranasal booster immunization with a replication-defective adenoviral recombinant, J. Immunol., 162(11), 6716, 1999.
80. Brandtzaeg, P., Farstad, I.N., and Haraldsen, G., Regional specialization in the mucosal immune system: Primed cells do not always home along the same track, Immunol. Today, 20(6), 267, 1999.
81. Hu, M.C.-T., Crowe, D.T., Weissman, I.L., and Holzmann, B., Cloning and expression of mouse integrin ßp(ß7): A functional role in Peyer's patch-specific lymphocyte homing, Proc. Natl. Acad. Sci. USA, 89(17), 8254, 1992.
82. Parr, E.L. and Parr, M.B., Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated Herpes Simplex type 2, J. Virol., 71(11), 8109, 1997.
83. Kilhamn, J., Jertbron, M., and Svennerholm, A.-M., Kinetics of local and systemic immune responses to an oral cholera vaccine given alone or together with acetylcysteine, Clin. Diagnost. Lab. Immunol., 5(2), 247, 1998.
84. Mestecky, J., Saliva as a manifestation of the common immune system, Ann. NY Acad. Sci., 694, 184, 1993.
85. Kozlowski, P.A., Cu-Uvin, S., Neutra, M.R., and Flanigan, T.P., Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women, Infect. Immun., 65(4), 1387, 1997.
86. Kirsching, C.J., Wesche, H., Merrill Ayres, T., and Rothe, M., Human Toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide, J. Exp. Med., 188(11), 2091, 1998.
87. Livingston, P., Ganglioside vaccines with emphasis on GM2, Semin. Oncol., 25(6), 636, 1998.
88. Lipford, G.B., Heeg, K., and Wagner, H., Bacterial DNA as immune cell activator, Trends Microbiol., 6(12), 496, 1998.
89. Mrsny, R.J., Daugherty, A.L., Short, S.M., Widmer, R., Siegel, M.W., and Keller, G.-A., Distribution of DNA and alginate in purulent cystic fibrosis sputum: Implications to pulmonary targeting strategies, J. Drug Targeting, 4(4), 233, 1996.
90. Pier, G.B., DesJardin, D., Grout, M., Garner, C., Bennett, S.E., Pekoe, G., Fuller, S.A., Thornton, M.O., Harkonen, W.S., and Miller, H.C., Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine, Infect. Immun., 62(9), 3972, 1994.
91. Cryz, Jr., S.J., Lang, A., Rudeberg, A., Wedgwood, J., Que, J.U., Furer, E., and Schaad, U., Immunization of cystic fibrosis patients with a Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine, Behring Inst. Mitt., 98, 345, 1997.
92. Goldblatt, D., Recent developments in bacterial conjugate vaccines, J. Med. Microbiol., 47(7), 563, 1998.
93. Agadjayan, M., Luo, P., Westerink, M.A.J., Carey, L.A., Hutchins, W., Steplewski, Z., Weiner, D.B., and Kieber-Emmons, T., Peptide mimicry of carbohydrate epitopes on human immunodefiency virus,Nat. Biotech., 15(6), 547, 1997.
94. Kieber-Emmons, T., Luo, P., Qiu, J., Agadjayan, M., Carey, L.A., Hutchins, W., Westerink, M.A.J., and Steplewski, Z., Peptide mimicry of adenocarcinoma-associated carbohydrate antigens, Hybridoma, 16(1), 3, 1997.
95. Kieber-Emmons, T., Luo, P., Qiu, J., Chang, T.Y., O, I., Blaszczyk-Thurin, M., and Steplewski, Z., Vaccination with carbohydrate peptide mimotopes promotes antitumor responses, Nat. Biotech., 17(7), 660, 1999.
96. Dighiero, G. and Rose, N.R., Critical self-epitopes are key to the understanding of self-tolerance and autoimmunity, Immunol. Today, 20(9), 423, 1999.
97. Sattentau, Q.J., HIV-1 antibody - Debris or virion?, Nat. Medicine, 3(4), 366, 1997.
98. Bachmaier, K., Neu, N., de la Maza, L.M., Pal, S., Hessel, A., and Penninger, J.M., Chlamydia infections and heart disease linked through antigenic mimicry, Science, 283(5406), 1335, 1999.
99. Virtanen, T., Zeiler, T., Rautiainen, J., and Mantyjarvi, R., Allergy to lipocalins: A consequence of misguided T-cell recognition of self and nonself?, Immunol. Today, 20(9), 398, 1999.
100. Quaratino, S., Thorpe, C.J., Travers, P.J., and Londei, M., Similar antigenic surfaces, rather than sequence homology, dictate T-cell epitope molecular mimicry, Proc. Natl. Acad. Sci. USA, 92(22), 10398, 1995.
101. Paolazzi, C.C., Perez, O., and De Filippo, J., Rabies vaccine: Developments employing molecular biology methods, Mol. Biotechnol., 11(2), 137, 1999.
102. Ward, S.J., Douce, G., Figueiredo, D., Dougan, G., and Wren, B.W., Immunogenicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domain of Clostridium difficile toxin A, Infect. Immun., 67(5), 2145, 1999.
103. Gorse, G.J., Keefer, M.C., Belshe, R.B., Matthews, T.J., Forrest, B.D., Hsieh, R.H., Koff, W.C., Hanson, C.V., Dolin, R., Weinhold, K.J., Frey, S.E., Ketter, N., and Fast, P.E., A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The national institute of allergy and infectious diseases AIDS vaccine evaluation group, J. Infect. Dis., 173(2), 330, 1996.
104. Spiller, O.B., Harris, C.L., and Morgan, B.P., Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells, J. Immunol. Methods, 224(1-2), 51, 1999.
105. Zhan, H., Liu, B., Reid, S.W., Aoki, K.H., Li, C., Syed, R.S., Karkaria, C., Koe, G., Sitney, K., Hayenga, K., Mistry, F., Savel, L., Dreyer, M., Katz, B. A., Schreurs J., Matthews, D.J., Cheetham, J.C., Egrie, J., Giebel, L.B., and Stroud, R.M., Engineering a soluble extracellular erythropoietin receptor (EPObp) in Pichia pastoris to eliminate microheterogeneity, and its complex with erythropoietin, Protein Eng., 12(6), 505, 1999.
106. Gorczynski, R.M., Cattral, M.S., Chen, Z., Hu, J., Lei, J., Min, W.P., Yu, G., and Ni, J., An immunoadhesin incorporating the molecule OX-2 is a potent immunosuppressant that prolongs allo-and xenograft survival, J. Immunol., 163(3), 1654, 1999.
107. Tacket, C.O., Mason, H.S., Losonsky, G., Clements, J.D., Levine, M.M., and Arntzen, C.J., Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato, Nat. Medicine, 4(5), 607, 1998.
108. Blumberg, R.S., Lencer, W.I., Zhu, X., Kim, H.S., Claypool, S., Balk, S.P., Saubermann, L.J., and Colgan, S.P., Antigen presentation by intestinal epithelial cells, Immunol. Lett., 69(1), 7-11, 1999.
109. Diehl, L., den Boer, A.T., Schoenberger, S.P., van der Voort, E.I., Schumacher, T.N., Melief, C.J., Offringa, R., and Toes, R.E., CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine efficacy, Nat. Medicine, 5(7), 774, 1999.
110. Aichele, P., Brduscha-Riem, K., Oehen, S., Odermatt, B., Zinkernagel, R.M., Hengartner, H., and Pircher, H., Peptide antigen treatment of naive and virus-immune mice: Antigen-specific tolerance versus immunopathology, Immunity, 6(5), 519, 1997.
111. Honeyman, M.C., Brusic, V., Stone, N.L., and Harrison, L.C., Neural network-based prediction of candidate T-cell epitopes, Nat. Biotech., 16(10), 966, 1998.
112. Mizzen, L., Immune responses to stress proteins: Applications to infectious disease and cancer, Biotherapy, 10(3), 173, 1998.
113. Schoenberger, S.P., van der Voort, E.I., Krietemeijer, G.M., Offringa, R., Melief, C.J., and Toes, R.E., Cross-priming of CTL responses in vivo does not require antigenic peptides in the endoplasmic reticulum of immunizing cells, J. Immunol., 161(8), 3808, 1998.
114. + CTL effector cells in mice by immunization with a stress protein-influenza virus nucleoprotein fusion molecule, Vaccine, 17(4), 373, 1999.
115. Donnelly, J.J. and Ulmer, J.B., DNA vaccines for viral diseases, Brazilian J. Med. Biol. Res., 32(2), 215, 1999.
116. Fomsgaard, A., HIV-1 DNA vaccines, Immunol. Lett., 65(1-2), 127, 1999.
117. Boyle, J-S., Brady, J.L., and Lew, A.M., Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction, Nature, 392(6674), 408, 1998.
118. Sasaki, S., Sumino, K., Hamajima, K., Fukushima, J., Ishii, N., Kawamoto, S., Mohri, H., Kensil, C.R., and Okuda, K., Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes, J. Virol., 72(6), 4931, 1998.
119. Ahlers, J.D., Takeshita, T., Pendleton, C.D., and Berzofsky, J. A., Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence, Proc. Natl. Acad. Sci. USA, 94(20), 10856, 1997.
120. Wandstrat, T.L., Kaplan Machlis, B., Temple, M.E., and Nahata, M.C., Tetravalent rotavirus vaccine, Ann. Pharmacother, 33(7-8), 833, 1999.
121. Conrad, D.A. and Jenson, H.B., Using acellular pertussis vaccines for childhood immunization; Potential benefits far outweigh potential risks, Postgraduate Med., 105(7), 165, 1999.
122. Barr, P.J. ,Gibson, H.L., Bathurst, I.C., Sabin, E.A., Medina-Selby, A., Coit, D., and Valenzuela, P., Recombinant subunit vaccines from yeast, Biotechnology, 13, 319, 1989.
123. Hayney, M.S., Grunske, M.M., and Boh, L.E., Lyme disease prevention and vaccine prophylaxis, Ann. Pharmacother., 33(6), 723, 1999.
124. Alves, A.M., Lasaro, M.O., Almeida, D.F., and Ferreira, L.C., New vaccine strategies against enterotoxigenic Escherichia coli I: DNA vaccines against the CFA/I fimbrial adhesin, Braz. J. Med. Biol. Res., 32(2), 223, 1999.
125. Wizemanm, T.M., Adamou, J.E., and Langermann, S., Adhesins as targets for vaccine development, Emerg. Infect. Dis., 5(3), 395, 1999.
126. Liljeqvist, S. and Stahl, S., Production of recombinant subunit vaccines: Protein immunogens, live delivery systems, and nucleic acid vaccines, J. Biotech., 73(1), 1, 1999.
127. Di Tommaso, A., Bartalini, M., Peppoloni, S., Podda, A., Rappuoli, R., and De Magistris, M.T., Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults, Vaccine, 15(11), 1218, 1997.
128. Del Giudice, G. and Rappuoli, R., Genetically derived toxoids for use as vaccines and adjuvants, Vaccine, 17(Suppl. 2), S44, 1999.
129. Connor, R.I., Korber, B.T.M., Graham, B.S., Hahn, B.H., Ho, D.D., Walker, B.D., Neumann, A.U., Vermund, S.H., Mestecky, J., Jackson, S., Fenamore, E., Cao, Y., Gao, F., Kalams, S., Kunstman, K.J., McDonald, D., McWilliams, N., Trkola, A., Moore, J.P., and Wolinsky, S.M., Immunological and virological analysis of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines, J. Virol., 72(2), 1552, 1998.
130. Funkhouser, A., Clements, M.L., Slome, S., Clayman, B., and Viscidi, R., Antibodies to recombinant gp160 in mucosal secretions and sera of persons infected with HIV-1 and seronegative vaccine recipients, AIDS Res. Hum. Retroviruses, 9(7), 627, 1993.
131. Kwong, P.D., Wyatt, R., Robinson, J., Sweet, R.W., Sodroski, J., and Hendrickson, W.A., Structure of an HIV gp120 envelope glycoprotein in a complex with the CD4 receptor and a neutralizing human antibody, Nature, 393(6686), 648, 1998.
132. Cocchi, F., DeVico, A.L., Garzino-Demo, A., Cara, A., Gallo, R.C., and Lusso, P., The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection, Nat. Medicine, 2(11), 1244, 1996.
133. Salzwedel, K., West, J.T., and Hunter, E., A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomian is important for Env-mediated fusion and virus infectivity, J. Virol., 73(3), 2469, 1999.
134. Ahlers, J.D., Dunlop, N., Pendleton, C.D., Newman, M., Nara, P.L., and Berzofsky, J.A, Candidate HIV type 1 multideterminant cluster peptide-P18MN vaccine constructs elicit type 1 helper T cells, cytotoxic T cells, and neutralizing antibody, all using the same adjuvant immunization, AIDS Res. Hum. Retroviruses, 12(4), 259, 1996.
135. Ozpolat, B., Rao, X.M., Powell, M.F., and Lachman, L.B., Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines, AIDS Res. Hum. Retroviruses, 14(5), 409, 1998.
136. Valenzuela, A., Blance, J., Krust, B., Franco, R., and Hovanessian, A.G., Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells, J. Virol., 71(11), 8289, 1997.
137. Karray, S. and Zouali, M., Identification of the B cell superantigen-binding site of HIV-1 gp120, Proc. Natl. Acad. Sci. USA, 94(4), 1356, 1997.
138. Kozlowski, P.A., Black, K.P., Shen, L., and Jackson, S., High prevelance of serum IgA HIV-1 infection-enhancing antibodies in HIV-infected persons; Masking by IgG, J. Immunol., 154(11), 6163, 1995.
139. Montefiori, D.C., Pantaleo, G., Fink, L.M., Zhou, J.T., Zhou, J.Y., Bilska, M., Miralles, G.D., and Fauci, A.S., Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors, J. Infect. Dis., 173(1), 60, 1996.
140. Fust, G., Enhancing antibodies in HIV infection, Parisitology, 115(Suppl.), S127, 1997.
141. Shibata, R., Igarashi, T., Haigwood, N., Buckler White, A., Ogert, R., Ross, W., Willey, R., Cho, M.W., and Martin, M.A., Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys, Nat. Medicine, 5(2), 142, 1999.
142. Giminez, H.B., Chisholm, S., Dornan, J., and Cash, P., Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies, Clin. Diagn. Lab. Immunol., 3(3), 280, 1996.
143. Ditzel, H.J., Parren, P.W.H.I., Binley, J.M., Sodroski, J., Moore, J.P., Barbas III, C.F., and Burton, D.R., Mapping the protein surface of human immunodefiency virus type 1 gp120 using human monoclonal antibodies from phage display libraries, J. Mol. Biol., 267(3), 684, 1997.
144. Neirynck, S., Deroo, T., Saelens, X., Vanlandschoot, P., Jou, W.M., and Fiers, W., A universal influenza A vaccine based on the extracellular domain of the M2 protein, Nat. Medicine, 5(10), 1157, 1999.
145. Gregoriadis, G., Genentic vaccine: Stategies for optimization, Pharmacol. Res., 15(5), 661, 1998.
146. Eldridge, J.H., Meulbroek, J.A., Staats, J.K., Tice, T.R., and Gilley, R.M., Vaccine-containing biodegradable microspheres specifically enter the gut-associated lyniphoid tissue following oral administration and induce a disseminated mucosal immune response, Adv. Exp. Med. Biol., 251, 191, 1989.
147. Kingsman, A.J., Adams, S.E., Burns, N.R., and Kingsman, S.M., Retroelement particles as purification, presentation, and targeting vehicles, Trends Biotech., 9(9), 303, 1991.
148. LiCalsi, C., Christerisen, T., Bennett, J.V., Philips, E., and Withham, C., Dry powder inhalation as a potential delivery method for vaccines, Vaccine, 17(13-14), 1796, 1999.
149. Ahlers, J.D., Pendleton, C.D., Dunlop, N., Minassian, A., Nara, P.L., and Berzofsky, J.A., Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations, J. Immunol., 150(12), 5647, 1993.
150. FitzGerald, D.J., Fryling, C.M., McKee, M.L., Vennari, J.C., Wrin, T., Cromwell, M.E., Daugherty, A.L., and Mrsny, R.J., Characterization of V3 loop-Pseudomonas exotoxin chimeras; Candidate vaccines for human immunodeficiency virus-1, J. Biol. Chem., 273(16), 9951, 1998.
151. Doling, A.M., Ballard, J.D., Shen, H., Krishna, K.M., Ahmed, R., Collier, R.J., and Starnbach, M.N., Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity, Infect. Immun., 67(7), 3290, 1999.
152. Szu, S.C., Taylor, D.N., Trofa, A.C., Clements, J.D., Shiloach, J., Sadoff, J.C., Bryla, D.A., and Robbins, J.B., Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines, Infect. Immun., 62(10), 4440, 1994.
153. Fattom, A., Schneerson, R., Watson, D.C., Karakawa, W.W., Fitzgerald, D., Pastan, I., Li, X., Shiloach, J., Bryla, D.A., and Robbins, J.B., Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A, Infect. Immun., 61(3), 1023, 1993.
154. Welch, P.G., Fattom, A., Moore, Jr., J., Schneerson, R., Shiloach, J., Bryla, D.A., Li, X., and Robbins, J.B., Safety and immunogenicity of Staphylococcus aureus type 5 capsular polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugate vaccine in patients on hemodialysis, J. Am. Soc. Nephrol., 7(2), 247, 1996.
155. Butler, J.C., Shapiro, E.D., and Carlone, G.M., Pneumococcal vaccines: History, current status, and future directions, Am. J. Med., 107(1A), 69S, 1999.
156. Poland, G.A., The burden of pneumococcal disease: The role of conjugate vaccines, Vaccine, 17(13-14), 1674, 1999.
157. Cohen, S., Alonso, M.J., and Langer, R., Novel approaches to controlled-release antigen delivery, Int. J. Technol. Assess Health Care, 10(1), 121, 1994.
158. Michalek, S.M., Childers, N.K., Katz, J., Dertzbaugh, M., Zhang, S., Russell, M.W., Macrina, F.L., Jackson, S., and Mestecky, J., Liposomes and conjugate vaccines for antigen delivery and induction of mucosal immune responses, Adv. Exp. Med. Biol., 327, 191, 1992.
159. Holmgren, J. and Lindholm, L., Cholera toxin, ganglioside receptors, and the immune response, Immunol. Commun., 5, 737, 1976.
160. Cryz, Jr., S.J., Furer, E., and Que, J.U., Synthesis and characterization of a Pseudomonas aeruginosa alginate-toxin A conjugate vaccine, Infect. Immun., 59(1), 45, 1991.
161. Frey, A., Neutra, M.R., and Robey, F.A., Peptomer aluminum oxide nanoparticle conjugates as systemic and mucosal vaccine candidates: Synthesis and characterization of a conjugate derived from the C4 domain of HIV-1MN gp120, Bioconjugate Chem., 8(3), 424, 1997.
162. Frezard, F., Liposomes: From biophysics to the design of peptide vaccines, Brazilian J. Med. Biol. Res., 32(2), 181, 1999.
163. Seong, S.Y., Cho, N.H., Kwon, I.C., and Jeong, S.Y., Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae, Infect. Immun., 67(7), 3587, 1999.
164. Edelman, R., Russell, R.G., Losonsky, G., Tall, B.D., Tacket, C.O., Levine, M.M., and Lewis, D.H., Immunization of rabbits with enterotoxigenic E. coli colonization factor antigen (CFA/I) encapsulated in biodegradable microspheres of poly (lactide-co-glycolide), Vaccine, 11(2), 155, 1993.
165. Cryz, Jr., S.J. and Gluck, R., Immunopotentiating reconstituted influenza virosomes as a novel antigen delivery system, Dev. Biol. Stand., 92, 219, 1998.
166. Conne, P., Gauthey, L., Vernet, P., Althaus, B., Que, J.U., Finkel, B., Gluck, R., and Cryz, Jr., S.J., Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients, Vaccine, 15(15), 1675, 1997.
167. Holzer, B.R., Hatz, C., Schmidt-Sissolak, D., Gluck, R., Althaus, B., and Egger, M., Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: A randomized controlled trial, Vaccine, 14(10), 982, 1996.
168. Holzer, B.R., Hatz, C., Schmidt-Sissolak, D., Gluck, R., Althaus, B., and Egger, M., Published erratum for: Immunogenicity and adverse effects of inactivated virosome versus alumadsorbed hepatitis A vaccine: a randomized controlled trial, Vaccine, 15(2), 245, 1997.
169. Nieland, J.D., Da Silva, D.M., Velders, M.P., de Visser, K.E., Schiller, J.T., Muller, M., and Kast, W.M., Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response, J. Cell Biochem., 73(2), 145, 1999.
170. Roy, P., Genetically engineered particulate virus-like structures and their use as vaccine delivery systems, Intervirology, 39(1-2), 62, 1996.
171. Ando, S., Tsuge, H., and Mayumi, T., Preparation of influenza virosome vaccine with muramyldipeptide derivative B30-MDP, J. Microencapsul., 14(1), 79, 1997.
172. Toda, S., Ishii, N., Okada, E., Kusakabe, K.I., Arai, H., Hamajima, K., Gorai, I., Nishioka, K., and Okuda, K., HIV-1 -specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes
173. Tabata, Y. and Ikada, Y., Synthesis of gelatin microspheres containing interferon, Pharmacol. Res., 6(5), 422, 1989.
174. Bui, T., Dykers, T., Hu, S.L., Faltynek, C.R., and Ho, R.J., Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein, J. Acquir. Immune Defic. Syndr., 7(8), 799, 1994.
175. Petrov, A.B., Kolenko, V.M., Koshkina, N.V., Zakirov, M.M., Bugaev, L.V., Semenova, I.B., Wiertz, E.J., and Poolman, J.T., Nonspecific modulation of the immune response with liposomal meningococcal lipopolysaccharide: Role of different cells and cytokines, Vaccine, 12(12), 1064, 1994.
176. Almeida, A.J., Alpar, H.O., and Brown, M.R.W., Immune response to nasal delivery of antigenically intact tetanus toxoid associated with poly(L-lactic acid) microspheres in rats, rabbits and guinea-pigs, J. Pharm. Pharmacol., 45, 198, 1993.
177. Hanes, J., Chiba, M., and Langer, R., Polymer microspheres for vaccine delivery, Pharm. Biotechnol., 6, 389, 1995.
178. Jankovic, D., Caspar, P., Zweig, M., Garcia-Moll, M., Showalter, S.D., Vogel, F.R., and Sher, A., Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120, J. Immunol, 159(5), 2409, 1997.
179. Schwendemann, S.P., Tobio, M., Joworoicz, M., Alonso, M.J., and Langer, R., New strategies for the microencapsulation of tetanus vaccine, J. Microencapsul., 15(3), 299, 1998.
180. Mathiowitz, E., Jacob, J.S., Jong, Y.S., Carino, G.P., Chickering, D.E., Chaturvedi, P., Santos, C.A., Vijayaraghavan, K., Montgomery, S., Bassett, M., and Morrell, C., Biologically erodable microspheres as potential oral drug delivery systems, Nature, 386(6623), 410, 1997.
181. Venkataprasad, N., Coombes, A.G., Singh, M., Rohde, M., Wilkinson, K., Hudecz, F., Davis, S.S., and Vordermeier, H.M., Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers, Vaccine, 17(15-16), 1814, 1999.
182. Herrmann, J.E., Chen, S., C., Jones, D.H., Tinsley-Brown, A., Fynan, E.F., Greenberg, H.B., and Farrar, G.H., Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles, Virology, 259(1), 148, 1999.
183. Jani, P.U., McCarthy, D.E., and Florence, A.T., Nanosphere and microsphere uptake via Peyer's patches: Observation of the rate of uptake in the rat after a single oral dose, Int. J. Pharm., 86, 239, 1992.
184. Lehr, C.-M. and Lee, V.H.L., Binding and transport of some bioadhesive plant lectins across Caco-2 cell monolayers, Pharmacol. Res., 10(12), 1796, 1993.
185. Gebert, A. and Hach, G., Differential binding of lectins to M cells and enterocytes in the rabbit cecum, Gastroenterology, 105, 1350, 1993.
186. Wilson, A.D., Robinson, A., Irons, L., and Stokes, C.R., Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen, Vaccine, 11(2), 113, 1993.
187. Pappo, J., Ermak, T.H., and Steger, H.J., Monoclonal antibody-directed targeting of fluorescent polystyrene microspheres to Peyer's patch M cells, Immunology, 73, 277, 1991.
188. Cleland, J.L., Single-administration vaccines: Controlled-release technology to mimic repeated immunizations, Trends Bio tech., 17(1), 25, 1999.
189. Chandrasekhar, U., Sihha, S., Bhagat, H.R., Sinha, V.B., and Srivastava, B.S., Comparative efficacy of biodegradable liposomes and microspheres as carriers for delivery of Vibrio cholera antigens in the intestine, Vaccine, 12(15), 1384, 1994.
190. Childers, N.K., Denys, F.R., McGee, N.F., and Michalek, S.M., Ultrastructural study of liposomes uptake by M cells of Peyer's patch: An oral vaccine system for delivery of purified antigen, Reg. Immunol., 3(1), 8, 1990.
191. Chen, H. and Langer, R., Magnetically-responsive polymerized liposomes as potential oral delivery vehicles, Pharmacol. Res., 14(4), 537, 1997.
192. Santiago, N., Mistein, S., Rivera, T., Garcia, E., Zaidi, T., Hong, H., and Bucher, D., Oral immunization of rats with proteinoid microspheres encapsulating influenza antigens, Pharmacol. Res., 10(1), 1243, 1993.
193. Aramaki, Y., Fujii, Y., Yahci, K., Kikuchi, H., and Tsuchiya, S., Activation of systemic and mucosal immune response following nasal administration ofliposomes, Vaccine, 12(13), 1241, 1994.
194. de Haan, A., Geerligs, H.J., Huchshorn, J.P., van Scharrenburg, G.J.M., Palache, A.M., and Wilschut, J., Mucosal immunoadjuvant activity of liposomes; Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes, Vaccine, 13(2), 155, 1995.
195. Ponchel, G., Montisci, M.-J., Dembri, A., Durrer, C., and Duchene, D., Mucoadhesion of colloidal particulate systems in the gastrointestinal tract, Eur. J. Pharm. Biopharm., 44, 25, 1997.
196. Witschi, C. and Mrsny, R.J., In vitro evaluation of microparticles and polymer gels for use as nasal platforms for protein delivery, Pharmacol. Res., 16(3), 382, 1999.
197. Marx, P.A., Compans, R.W., Gettie, A., Staas, J.K., Gilley, R.M., Mulligan, M.J., Yamshchikov, G.V., Chen, D., and Eldridge, J.H., Protection against vaginal SIV transmission with microencapsulated vaccine, Science, 260(5112), 1323, 1993.
198. Kaufmann, S.H. and Hess, J., Impact of intracellular location of and antigen display by intracellular bacteria: Implications for vaccine development, Immunol. Lett., 65(1-2), 81, 1999.
199. Cripps, A. W., Dunkley, M.L., and Clancy, R.L., Mucosal and systemic immunizations with killed Pseudomonas aeruginosa protect against acute respiratory infections in rats, Infect. Immun., 62(4), 1427, 1994.
200. Sadoff, J.C., Ballou, W.R., Baron, L.S., Majarian, W.R., Brey, R.N., Hockmeyer, W.T., Young, J.F., Cryz, Jr., S.J., Ou, J., and Lowell, G.H., Oral Salmonella typhimurium vaccine expressing circumsporozoite protein protects against malaria, Science, 240(4850), 336, 1988.
201. + cytotoxic T cells, J. Exp. Med., 172(4), 1083, 1990.
202. Ikonomidis, G., Paterson, Y., Kos, F.J., and Portnoy, D.A., Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes, J. Exp. Med., 180(6), 2209, 1994.
203. Monath, T.P., Soike, K., Levenbook, I., Zhang, Z.X., Arroyo, J., Delagrave, S., Myers, G., Barrett, A.D., Shope, R.E., Ratterree, M., Chambers, T.J., and Guirakhoo, F., Recombinant, chimæric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic, and protective in nonhuman primates, Vaccine, 17(15-16), 1869, 1999.
204. Evans, D.J., McKeating, J., Meredith, J.M., Burke, K.L., Katrak, K., John, A., Ferguson, M., Minor, P.D., Weiss, R.A., and Almond, J.W., An engineered poliovirus chimera elicits broadly reactive HIV-1 neutralizing antibodies, Nature, 339(6223), 385, 1989.
205. Anderson, M.J., Porter, D.C., Moldoveanu, Z., Fletcher, 3rd, T.M., McPherson, S., and Morrow, C.D., Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins, AIDS Res. Hum. Retroviruses, 13(1), 53, 1997.
206. Raikwar, S.P., Malik, P., Singh, O., and Vrati, S., Recombinant adenovirus synthesizing cell surface-anchored beta hCG induces bioneutralizing antibodies in rats, Gene, 190(1), 197, 1997.
207. Neutra, M.R., Pringault, E., and Kraehenbuhl, J.-P., Antigen sampling across epithelial barriers and induction of mucosal immune responses, Annu. Rev. Immunol., 14, 275, 1996.
208. Frey, A., Giannasca, K.T., Weltzin, R., Giannasca, P.J., Reggio, H., Lencer, W.I., and Neutra, M.R., Role of the glycocalyx in regulating access of microparticles to apical plasma membrane of intestinal epithelial cells: Implications for microbial attachment and oral vaccine targeting J. Exp. Med., 184(3), 1045, 1996.
209. Johnson, R.P., Live attenuated AIDS vaccines: Hazards and hopes, Nat. Medicine, 5(2), 154, 1999.
210. Bresee, J.S., Glass, R.I., Ivanoff, B., and Gentsch, J.R., Current status and future priorities for rotovirus vaccine development, evaluation and implementation in developing countries. Vaccine, 17(18), 2207, 1999.
211. Foster, R.H. and Noble, S., Bivalent cholera and typhoid vaccine, Drugs, 58(1), 91, 1999.
212. Pouwels, P.H., Leer, R.J., Shaw, M., Heijne den Bak-Glashouwer, M.J., Tielen, F.D., Smit, E., Martinez, B., Jore, J., and Conway, P.L., Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes, Int. J. Food Microbiol., 41(2), 155, 1998.
213. Ginsberg, H.S., The ups and downs of adenovirus vectors, Bull. NY Acad. Med., 73(1), 53, 1996.
214. Sasaki, S., Hamajima, K., Fukushima, J., Ihata, A., Ishii, N., Gorai, I., Hirahara, F., Mohri, H., and Okuda, K., Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine, Infect. Immun., 66(2), 823, 1998.
215. Uehling, D.T., Hopkins, W.J., Dahmer, L.A., and Balish, E., Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection, J. Urol., 152(6/2), 2308, 1994.
216. Lee, A.H., Suh, Y.S., Sung, J.H., Yang, S.H., and Sung, Y.C., Comparison of various expression plasmids for the induction of immune response by DNA immunization, Mol. Cells, 7(4), 495, 1997.
217. Falo, Jr., L.D., Targeting the skin for genetic immunization, Proc. Assoc. Am. Physicians, 111(3), 211, 1999.
218. Morita, A. and Takashima, A., Roles of Langerhans cells in genetic immunization, J. Dermatol. Sci., 20(1), 39, 1998.
219. Glenn, G.M., Scharton-Kersten, T., Vassell, R., Matyas, G.R., and Alving, C.R., Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants, Infect. Immun., 67(3), 1100, 1999.
220. Fan, H., Lin, Q., Morrissey, G.R., and Khavari, P.A., Immunization via hair follicles by topical application of naked DNA to normal skin, Nat. Biotech., 17(9), 870, 1999.
221. Shi, Z., Curiel, D.T., and Tang, D.C., DNA-based noninvasive vaccination onto the skin, Vaccine, 17(17), 2136, 1999.
222. Belperron, A.A., Feltquate, D., Fox, B.A., Horii, T., and Bzik, D.J., Immune responses induced by gene gun or intramuscular injection of DNA vaccines that express immunogenic regions of the serine repeat antigen from Plasmodium falciparum, Infect. Immun., 67(10), 5163, 1999.
223. Waine, G.J., Mazzer, D.R., and McManus, D.P., DNA immunization by intramuscular injection or gene gun induces specific IgG antibodies against a Schistosoma japonia 22 kDa antigen Sj22, when fused to the murine Ig K-chain secretory leader sequence, Parasite Immunol., 21(1), 53, 1999.
224. Surman, D.R., Irvine, K.R., Shulman, E.P., Allweis, T.M., Rosenberg, S.A., and Restifo, N.P., Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization, J. Immunol. Methods, 214(1-2), 51, 1998.
225. Lundholm, P., Asakura, Y., Hikula, J., Lucht, E., and Warhern, B., Induction of mucosal IgA by a novel jet delivery technique for HIV-1 DNA, Vaccine, 17(15-16), 2036, 1999.
226. Mestecky, J., Michalek, S.M., Moldoveanu, Z., and Russell, M.W., Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans, Behring Inst. Mitt., 98, 33, 1997.
227. Kyd, J.M. and Cripps, A.W., Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: An overview, Vaccine, 17(13-14), 1775, 1999.
228. Mrsny, R.J., Daugherty, A.L., Fryling, C.M., and FitzGerald, D.J., Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses, Vaccine, 17(11-12), 1425, 1999.
229. Zhang, D.J., Yang, X., Shen, C., and Brunham, R.C., Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain, Immunology, 96(2), 314, 1999.
230. Haensler, J., Verdelet, C., Sanchez, V., Girerd-Chambaz, Y., Bonnin, A., Trannoy, E., Krishnan, S., and Meulien, P., Intradermal DNA immunization by using jet-injectors in mice and monkeys, Vaccine, 17(7-8), 628, 1999.
231. Daugherty, A.L., Cleland, J.L., Duenas, E.M., and Mrsny, R.J., Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres, Eur. J. Pharm. Biopharm., 44(1637), 89, 1997.
232. Lutwick, L.I., Unconventional vaccine targets: Immunization for pregnancy, peptic ulcer, gastric cancer, and atherosclerosis, Infect. Dis. Clinics North Am., 13(1), 245, 1999.
233. Martin, T., Parker, S.E., Hedstrom, R., Le, T., Hoffman, S.L., Norman, J., Hobart, P., and Lew, D., Plasmid DNA malaria vaccine: The potential for genomic integration after intramuscular injection, Hum. Gene Ther., 10(5), 759, 1999.
234. Morrow, C.D., Novak, M.J., Ansardi, D.C., Porter, D.C., and Moldoveanu, Z., Recombinant viruses as vectors for mucosal immunity, Curr. Top. Microbiol. Immunol., 236, 255, 1999.
235. Caley, I.J., Betts, M.R., Irlbeck, D.M., Davis, N.L., Swanstrom, R., Frelinger, J.A., and Johnston, R.E., Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector, J. Virol, 71(4), 3031, 1997.
236. Belyakov, I.M., Wyatt, L.S., Ahlers, J.D., Earl, P., Pendleton, C.D., Kelsall, B.L., Strober, W., Moss, B., and Berzofsky, J.A, Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein, J. Virol., 72(10), 8264, 1998.
237. Ambriovic, A., Adam, M., Monteil, M., Paulin, D., and Eloit, M., Efficacy of replication-defective adenovirus-vectored vaccines: Protection following intramuscular injection is linked to promoter efficiency in muscle representative cells, Virology, 238(2), 327, 1997.
238. Bronte, V., Carroll, M.W., Goletz, T.J., Wang, M., Overwijk, W.W., Marincola, F., Rosenberg, S.A., Moss, B., and Restifo, N.P., Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine, Proc. Natl. Acad. Sci. USA, 94(7), 3183, 1997.
239. Eloit, M., Adam, M., Gallais, I., and Fournier, A., High level of transgene expression in cell cultures and in the mouse by replication-incompetent adenoviruses harboring modified VAI genes, J. Virol., 71(7), 5375, 1997.
240. Yarosh, O.K., Wandeler, A.I., Graham, F.L., Campbell, J.B., and Prevec, L., Human adenovirus type 5 vectors expressing rabies glycoprotein, Vaccine, 14(13), 1257, 1996.
241. Belyakov, I.M., Moss, B., Strober, W., and Berzofsky, J.A., Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity, Proc. Natl. Acad. Sci. USA, 96(8), 4512, 1999.
242. Ulrich, R., Lundqvist, A., Meisel, H., Koletzki, D., Sjonander, K.B., Gelderblom, H.R., Borisova, G., Schnitzler, P., Darai, G., and Kruger, D.H., Chimæric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model, Vaccine, 16(2-3), 272, 1998.
243. Mandl, S., Sigal, L.J., Rock, K.L., and Andino, R., Poliovirus vaccine vectors elicit antigen-specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen, Proc. Natl. Acad. Sci. USA, 95(14), 8216, 1998.
244. Kruger, D.H., Ulrich, R., and Gerlich, W.H., Chimeric virus-like particles as vaccines, J. Biol. Chem., 380(3), 275, 1999.
245. 2 antibody,Nat. Biotech., 17(2), 181, 1999.
246. Huang, J.-F., Yang, Y., Sepulveda, H., Shi, W., Hwang, I., Peterson, P.A., Jackson, M.R., Sprent, J., and Cai, Z., TDR-mediated internalization of peptide-MHC complexes acquired by T cells, Science, 286(5441), 952, 1999.
247. Rendahl, K.G., Leff, S.E., Otten, G.R., Spratt, S.K., Bohl, D., Roey, M.V., Donahue, B.A., Cohen, L.K., Mandel, R.J., Danos, O., and Snyder, R.O., Regulation of gene expression in vive following transduction by two separate rAAV vectors, Nat. Biotech., 16(8), 757, 1998.
248. Ploegh, H.L., Viral strategies of immune evasion, Science, 280(5361), 248, 1998.
249. Price, D.A., Klenerman, P., Booth, B.L., Phillips, R.E., and Sewell, A.K., Cytotoxic T lymphocytes, chemokines, and antiviral immunity, Immunol. Today, 20(5), 212, 1999.
250. Trapani, J.A., Sutton, V.R., and Smyth, M.J., CTL granules: Evolution of vesicles essential for combating virus infections, Immunol. Today, 20(8), 351, 1999.
251. Palese, P., Muster, T., Zheng, H., O'Neill, R., and Garcia-Sastre, A., Learning from our foes: A novel vaccine concept for influenza virus, Arch. Virol., 15(Suppl.), 131, 1999.
252. Guirakhoo, F., Zhang, Z.X., Chambers, T.J., Delagrave, S., Arroyo, J., Barrett, A.D., and Monath, T.P., Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis, Virology, 257(2), 363, 1999.
253. Li, W., Berencsi, K., Basak, S., Somasundaram, R., Ricciardi, R.P., Gonczol, E., Zaloudik, J., Linnenbach, A., Maruyama, H., Miniou, P., and Herlyn, D., Human colorectal cancer (CRC) antigen CO17-1A/GA733 encoded by adenovirus inhibits growth of established CRC cells in mice, J. Immunol., 159(2), 763, 1997.
254. Zhai, Y., Yang, J.C., Kawakami, Y., Spiess, P., Wadsworth, S.C., Cardoza, L.M., Couture, L.A., Smith, A.E., and Rosenberg, S.A., Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy, J. Immunol., 156(2), 700, 1996.
255. Zhang, H.G., Zhou, T., Yang, P., Edwards 3rd., C.K., Curiel, D.T., and Mountz, J.D., Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver, Hum. Gene Ther., 9(13), 1875, 1998.
256. Grillot-Courvalin, C., Goussard, S., Huetz, F., Ojcius, D.M., and Courvalin, P., Functional gene transfer from intracellular bacteria to mammalian cells, Nat. Biotech., 16(8), 862, 1998.
257. Killeen, K., Spriggs, D., and Mekalanos, J., Bacterial mucosal vaccines: Vibrio cholerae as a live attenuated vaccine/vector paradigm, Curr: Top. Microbiol. Immunol., 236, 237, 1999.
258. Steidler, L., Robinson, K., Chamberlain, L., Schofield, K.M., Remaut, E., Le Page, R.W., and Wells, J.M., Mucosal delivery of murine interleukin-2 (IL-2) and IL-6 by recombinant strains of Lactococcus lactis coexpressing antigen and cytokine, Infect. Immun., 66(7), 3183, 1998.
259. Eko, F.O., Witte, A., Huter, V., Kuen, B., Furst-Ladani, S., Haslberger, A., Katinger, A., Hensel, A., Szostak, M.P., Resch, S., Mader, H., Raza, P., Brand, E., Marchart, J., Jechlinger, W., Haidinger, W., and Lubitz, W., New strategies for combination vaccines based upon the extended recombinant bacterial ghost system, Vaccine, 17(13-14), 1643, 1999.
260. Hess, J., Dietrich, G., Gentschev, I., Miko, D., Goebel, W., and Kaufmann, S.H., Protection against murine listeriosis by an attenuated recombinant Salmonella typhimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase, Infect. Immun., 65(4), 1286, 1997.
261. Harty, J.T. and Bevan, M.J., Responses of CD8+ T cell to intracellular bacteria, Curr. Opin. Immunol., 11(1), 89, 1999.
262. Lowrie, D.B., Tascon, R.E., Bonato,V.L., Lima, V.M., Faccioli, L.H., Stavropolous, E., Colston, M.J., Hewinson, R.G., Moelling, K., and Silva, C.L., Therapy of tuberculosis in mice by DNA vaccination, Nature, 400(6741), 269, 1999.
263. Robertson, J. and Griffiths, E., WHO guidelines for assuring the quality of DNA vaccines, Biologicals, 26(3), 205, 1998.
264. Boyle, J.S., Barr, I.G., and Lew, A.M., Strategies for improving responses to DNA vaccrines, Mol. Med., 5(1), 1, 1999.
265. Weiner, D.B. and Kennedy, R.C., Genetic vaccines, Sci. Am., 281(1), 50-57, 1999.
266. Kowalczyk, D.W. and Ertl, H.C., Immune responses to DNA vaccines, Cell. Molec. Life Sci., 55(5), 751, 1999.
267. Slater, J.E., Paupore, E., Zhang, Y.T., and Colberg-Poley, A.M., The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine, J. Allergy Clin. Immunol., 102(3), 469, 1998.
268. Shen, G.Q., Shoenfeld, Y., and Peter, J.B., Anti-DNA, antihistone, and antinucleosome antiobodies in systemic lupus erythematosus and drug-induced lupus, Clin. Rev. Allergy Immunol., 16(3), 321, 1998.
269. Murakami, M., Gurski, K.J., and Steller, M.A., Human papillomavirus vaccines for cervical cancer, J. Immunother., 22(3), 212, 1999.
270. Ying, H., Zaks, T.Z., Wang, R.F., Irvine, K.R., Kammula, U.S., Marincola, F.M., Leitner, W.W., and Restifo, N.P., Cancer therapy using a self-replicating RNA vaccine, Nat. Medicine, 5(7), 823, 1999.
271. Oliveira, S.C., Rosinha, G.M., de Brito, C.F., Fonseca, C.T., Afonso, R.R., Costa, M.C., Goes, A.M., Rech, E.L., and Azevedo, V., Immunological properties of gene vaccines delivered by different routes, Brazilian J. Med. Biol. Res., 32(2), 207, 1999.
272. Li, Z., Howard, A., Kelley, C., Delogu, G., Collins, F., and Morris, S., Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences, Infect. Immun., 67(9), 4780, 1999.
273. Mandl, C.W., Aberle, J.H., Aberle, S.W., Holzmann, H., Allison, S.L., and Heinz, F.X., In vitro-synthesized infectious RNA as a attenuated live vaccine in a flavivirus model, Nat. Medicine, 4(12), 1438, 1998.
274. Takashima, A. and Monta, A., Dendritic cells in genetic immunization., J. Leukoc. Biol., 66(2), 350, 1999.
275. Eilat, D. and Napars tek, Y., Anti-DNA autoantibodies: A puzzle of autoimmune phenomena, Immunol. Today, 20(8), 339, 1999.
276. Roman, M., Martin-Orozco, E., Goodman, J.S., Nguyen, M.-D., Sato, Y., Ronaghy, A., Kornbluth, R.S., Richman, D.D., Carson, D.A., and Raz, E., Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants, Nat. Medicine, 3(8), 849, 1997.
277. Horner, A.A., Ronaghy, A., Cheng, P.M., Nguyen,M .D., Cho, H.J., Broide, D., and Raz, E., Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol., 190(1), 77, 1998.
278. Tsunoda, I., Tolley, N.D., Theil, D.J., Whitton, J.L., Kobayashi, H., and Fujinami, R.S., Exacerbation of viral and autoimmune animal models of multiple sclerosis by bacterial DNA, Brain Pathol., 9(3), 481, 1999.
279. McCluskie, M.J., and Davis, H.L., CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice, J. Immunol., 161(9), 4463, 1998.
280. Oxenius, A., Martinic, M.M., Hengartner, H., and Klenerman, P., CpG-containing oligonucleotides are efficient adjuvants for induction of protective antiviral immune responses with T-cell peptide vaccines, J. Virol., 73(5), 4120, 1999.
281. Deng, G.-M., Nilsson, I.-M., Verdrengh, M., Collins, L.V., and Tarkowsi, A., Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis, Nat. Medicine, 5(6), 702, 1999.
282. Del Giudice, G., Pizza, M., and Rappuoli, R., Molecular basis of vaccination, Mol. Aspects Med., 19(1), 1, 1999.
283. Pittet, J.F., Hashimoto, S., Pian, M., McElroy, M.C., Nitenberg, G., and Wiener-Kronish, J.P., Exotoxin A stimulates fluid resorption from distal airspaces of lung in anesthetized rats, Am. J. Physiol., 270(2 Pt. 1), L232, 1996.
284. Lencer, W.I., Moe. S., Rufo, P.A., and Madara, J.L., Transcytosis of cholera toxin subunits across model human intestinal epithelia, Proc. Natl. Acad. Sci. USA, 92(22), 10094, 1995.
285. Lord, J.M. and Roberts, L.M., Toxin entry: Retrograde transport through the secretory pathway, J. Cell Biol., 140(4), 733, 1998.
286. Marinaro, M., Di Tommaso, A., Uzzau, S., Fasano, A., and De Magistris, M.T., Zona occludins toxin is a powerful adjuvant for intranasally delivered antigens, Infect. Immun., 67(3), 1287, 1999.
287. Daugherty, A.L., McKee, M.L., FitzGerald, D.J., and Mrsny, R.J., Epithelial applicationof Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node, J. Controlled Rel., 65, 297, 2000.
288. Noakes, K.L., Teisserenc, H.T., Lord, J.M., Dunbar, P.R., Cerundolo, V., and Roberts, L.M., Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway, FEBS Lett., 453(1-2), 95, 1999.
289. Yamamoto, S., Kiyono, H., Yamamoto, M., Imaoka, M., Yamamoto, K., Fujihashi, K., van Ginkel, F.W., Noda, M., Takeda, Y., and McGhee, J.R., A non-toxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity, Proc. Natl. Acad. Sci. USA, 94(10), 5267, 1997.
290. Rappuoli, R., Pizza, M., Douce, G., and Dougan, G., Structure and mucosal adjuvancy of cholera and Eschericia coli heat-labile enterotoxins, Immunol. Today, 20(11), 493, 1999.
291. Williams, N.A., Hirst, T.R., and Nashar, T.O., Immune modulation by the cholera-like enterotoxins: From adjuvant to therapeutic, Immunol. Today, 20(2), 95, 1999.
292. Schiller, J.T., Papillomavirus-like particle vaccines for cervical cancer,Mol. Med. Today, 5(5), 209, 1999.
293. Rudolf, M.P., Nieland, J.D., DaSilva, D.M., Velders, M.P., Muller, M., Greenstone, H.L., Schiller, J.T., and Kast, W.M., Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles, Biol. Chem., 380(3), 335, 1999.
294. Balmelli, C., Roden, R., Potts, A., Schiller, J., De Grandi, P., and Nardelli-Haefliger, D., Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions, J. Virol, 72(10), 8220, 1998.
295. Bontkes, H.J., de Gruijl, T.D., Walboomers, J.M., Schiller, J.T., Dillner, J., Helmerhorst, T.J., Verheijen, R.H., Scheper, R.J., and Meijer, C.J., Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16, J. Gen. Virol., 80(Pt 2), 409, 1999.
296. Sultan, F., Jin, L.-L., Jobling, M.G., Holmes, R.K., and Stanley Jr, S.L., Mucosal immunogenicity of a holotoxin-like molecule conaining the serine-rich Entamoeba histolytica protein (SREHP) fused to the A2 domain of cholera toxin, Infect. Immun., 66(2), 462, 1998.
297. Foss, D.L. and Murtaugh, M.P., Mucosal immunogenicity and adjuvanticity of cholera toxin in swine, Vaccine, 17(7-8), 788, 1999.
298. Agren, L.C., Ekman, L., Lowenadler, B., Nedrud, J.G., and Lycke, N.Y., Adjuvanticity of cholera toxin Al-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity, J. Immunol., 162(4), 2432, 1999.
299. Blanchard, T.G., Lycke, N., Czinn, S.J., and Nedrud, J.G., Recombinant cholera toxin B subunit is not an effective mucosal adjuvant to oral immunization of mice against Helicobacter felis, Immunology, 94(1), 22, 1998.
300. Fontana, M., Dunipace, A.J., Stookey, G.K., and Gregory, R.L., Intranasal immunization against dental caries with a Streptococcus mutans-enriched fimbrial preparation, Clin. Diag. Lab. Immunol., 6(3), 405, 1999.
301. Arakawa, T., Yu, J., Chong, D.K.X., Hough, J., Engen, P.C., and Langridge, W.H.R., A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes, Nat. Biotech., 16(10), 934, 1998.
302. Nakagawa, I., Takahashi, L, Kiyono, H., McGhee, J.R., and Hamada, S., Oral immunzation with the B subunit of the heat-labile enterotoxin of Escherichia coli induces early Th1 and late Th2 cytokine expression in Peyer's patches, J. Infect. Dis., 173(6), 1428, 1996.
303. Choi, A.H., Basu, M., McNeal, M.M., Clements, J.D., and Ward, R.L., Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 and VP6 protein, J. Virol, 73(9), 7574, 1999.
304. Ekstrom, J., Hu, K.F., Bengtsson, K.L., and Morein, B., Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions, Vaccine, 17(20-21), 2690, 1999.
305. Grdic, D., Smith, R., Donachie, A., Kjerrulf, M., Hornquist, E., Mowat, A., and Lycke, N., The mucosal adjuvant effects of cholera toxin and immune-stimulating complexes differ in their requirement for IL-12, indicating different pathways of action, Eur. J. Immunol., 29(6), 1774, 1999.
306. Porgador, A., Staats., H.F., Itoh, Y., and Kelsall, B.L., Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: Selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue, Infect. Immun., 66(12), 5876, 1998.
307. Imaoka, K., Miller, C.J., Kubota, M., McChesney, M.B., Lohman, B., Yamamoto, M., Fujihashi, K., Someya, K., Honda, M., McChee, J.R., and Kiyono, H., Nasal immunization of nonhuman primates with simian immunodeficiency virus p55gag and cholera toxin adjuvant induces a Th1/Th2 help for virus-specific immune responses in reproductive tissues, J. Immunol, 161(11), 5952, 1998.
308. Cong, Y., Weaver, C.T., and Elson, C.O., The mucosal adjuvanticity of cholera toxin involves enhancement of costimulatory activity by selective up-regulation of B7.2 expression, J. Immunol, 159(11), 5301, 1997.
309. Yamamoto, S., Kiyono, H., Yamamoto, M., Batanero, E., Kweon, M.N., Otake, S., Azuma, M., Takeda, Y., and McGhee, J.R., Direct effects of antigen-presenting cells and T lymphocytes explain the adjuvancy of nontoxic cholera toxin mutant, J. Immunol., 162(12), 7015, 1999.
310. Braun, M.C., He, J., Wu, C. Y., and Kelsall, B.L., Cholera toxin suppresses interleukin (IL)-12 production and IL-12 receptor betal and beta2 chain expression, J. Exp. Med., 189(3), 541, 1999.
311. Weidermann, U., Jahn-Schmid, B., Repa, A., Kraft, D., and Ebner, C., Modulation of an allergic immune response via the mucosal route in a murine model of inhalative type-I allergy, Int. Arch. Allergy Immunol, 118(2-4), 129, 1999.
312. Agren, L.C., Lowenadler, B., and Lycke, N.Y., A novel concept in mucosal adjuvanticity: The CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates enzymatically active cholera toxin Al subunit, Immunol Cell Biol., 76(3), 280, 1999.
313. Tamura, S., Yakanaka, A., Shimohara, M., Tomita, T., Komase, K., Tsuda, Y., Suziki, Y., Nagamine, T., Kawahara, K., and Danbara, H., Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine, Vaccine, 12(5), 419, 1994.
314. de Haan, A., Verweij, W.R., Feil, I.K., Hotrop, M., Hol, W.G., Agsteribbe, E., and Wilschut, J., Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Eschericia coli heat-labile enterotoxin and its B subunit, Immunology, 94(3), 424, 1998.
315. de Haan, A., Hotrop, M., Verweij, W.R., Agsteribbe, E., and Wilschut, J., Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Eseherichia coli heat-labile enterotoxin, Immunology, 97(4), 706, 1999.
316. Gluck, U., Gebbers, J.O., and Gluck, R., Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers, J. Virol, 73(9), 7780, 1999.
317. Dubois, A., Lee, C.K., Fiala, N., Kleanthous, H., Mehlman, P.T., and Monath, T, Immunization against natural Helicobacter pylori infection in nonhuman primates, Infect. Immun., 66(9), 4340, 1998.
318. Michetti, P., Kreiss, C., Kotloff, K.L., Porta, N., Blanco, J.L., Bachmann, D., Herranz, M., Saldinger, P.F., Corthesy-Theulaz, I, Losonsky, G., Nichols, R., Simon, J., Stolte, M., Ackerman, S., Monath, T.P., and Blum, A.L., Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults, Gastroenterology, 116(4), 804, 1999.
319. Dale, J.B. and Chiang, E.G., Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections, J. Infect. Dis., 171(4), 1038, 1995.
320. Hazama, M., Mayumi-Aono, A., Miyazaki, T., Himuma. S., and Fujisawa, Y., Intranasal immunization against herpes simplex virus infection by using a recombinat glycoprotein D fused with immunomodulating proteins, the B subunit of Esherichia coli heat-labile enterotoxin and interleukin-2, Immunology, 78(4), 643, 1993.
321. Sewami, C.R, Bagdasarian, M.M., Ireland, J.J., and Bagdasaian, M., Display of an inhibin epitope in the surface-exposed loop of E. coli heat-labile enterotoxin B subunit, Vaccine, 17(16), 1611, 1998.
322. Komase, K., Tamura, S., Matsuo, K., Watanabe, K., Hattori, N., Odaka, A., Suzuki, Y., Kurata, T., and Aizawa, C., Mutants of Echerichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine, Vaccine, 16(3-4), 248, 1998.
323. McNeal, M.M., Rae, M.N., Bean, J.A., and Ward, R.L., Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles, J. ViroL, 73(9), 7565, 1999.
324. Carenas-Freytag, L., Cheng, E., Mayeux, P., Domer, J.E., and Clements, J.D., Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis, Infect. Immun., 67(2), 826, 1999.
325. Barackman, J.D., Ott, G., and O'Hagan, D.T., Intranasal immunization of mice with influenza vacine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization, Infect. Immun., 67(8), 4276, 1999.
326. Chong, C., Friberg, M., and Clements, J.D., LT(R192G), a nontoxic mutant of the heatlabile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella ssp, Vaccine, 16(7), 732, 1998.
327. Partidos, C.D., Salani, B.F., Pizza, M., and Rappuoli, R., Heat-labile enterotoxin of Escherichia coli and its site-directed mutant LTK63 enhance the proliferative and cytotoxic T-cell responses to intranasally co-immunized synthetic peptides, Immunol. Lett., 67(3), 209, 1999.
328. Douce, G., Giannelli, V., Pizza, M., Lewis, D., Everest, P., Rappuoli, R., and Dougan, G., Geneteically detoxified mutants of the heat-labile toxin from Esherichia coli are able to act as oral adjuvants, Infect. Immun., 67(9), 4400, 1999.
329. O'Dowd, A.M., Botting, C.H., Precious, B., Shawcross, R., and Randall, R.E., Novel modifications to the C-terminus of LTB that facilitate site-directed chemical coupling of antigens and the development of LTB as a carrier for mucosal vaccines, Vaccine, 17(11-12), 1442, 1999.
330. Pollack, M., Taylor, N.S., and Callahan, L.T., Exotoxin production by clinical isolates of Pseudomonas aeruginosa, Infect. Immun., 15, 776, 1977.
331. Hwang, J., FitzGerald, D. J., Adhya, S., and Pastan, I., Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli, Cell, 48, 129, 1987.
332. Morimoto, H. and Bonavida, B., Diphtheria toxin-and Pseudomonas A toxin-mediated apoptosis: ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-a, J. Immunol, 149(6), 2089, 1992.
333. Donnelly, J.J., Ulmer, J.B., Hawe, L.A., Friedman, A., Shi, X.P., Leander, K.R., Shiver, J.W., Oliff, A.I., Martinez, D., Montgomery, D., and Liu, M. A., Targeted delivery of peptide epitopes to class 1 major histocompatibility molecules by a modified Pseudomonas extoxin, Proc. Natl. Acad. Sci. USA, 90(8), 3530, 1993.
334. Chaudhary, V.K., Jinno, Y., Gallo, M.G., FitzGerald, D., and Pastan, I., Mutagenesis of Pseudomonas exotoxin in identification of sequences responsible for the animal toxicity, J. Biol. Chem., 265(27), 16306, 1990.
335. Lee, R.S., Tartour, E., van der Bruggen, P., Vantomme, V., Joyeux, I., Goud, B., Fridman, W.H., and Johannes, L., Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin, Eur. J. Immunol., 28(9), 2726, 1998.
336. Chengalvala, M.V., Bhat, R.A., Bhat, B.M., Vernon, S.K., and Lubeck, M.D., Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid, Vaccine, 17(9-10), 1035, 1999.
337. Goletz, T.J., Klimpel, K.R., Arora, N., Leppla, S.H., Keith, J.M., and Berzofsky, J.A., Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp 120-anthrax toxin fusion protein, Proc. Natl. Acad. Sci. USA, 94(22), 12059, 1997.
338. Carbonetti, N.H., Irish, T.J., Chen, C.H., O'Connell, C.B., Hadley, G.A., McNamara, U., Tuskan, R.G., and Lewis, G.K., Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway, Infect. Immun., 67(2), 602, 1999.
339. Fayolle, C., Ladant, D., Karimova, G., Ullmann, A., and Leclerc, C., Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J. Immunol, 162(7), 4157, 1999.
340. Roberts, M., Bacon, A., Rappuoli, R., Pizza, M., Cropley, I., Douce, G., Dougan, G., Marinaro, M., McGhee, J., and Chatfield, S., A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins, Infect. Immun., 63(6), 2100, 1995.
341. Robbins, J.B., Schneerson, R., Trollfors, B., Taranger, J., and Lagergard, T., Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid, Dev. Biol. Stand., 95, 155, 1998.
342. Toes, R.E., Schoenberger, S.P., van der Voort, E.I., Kast, W.M., Hoeben, R.C., Melief, C.J., and Offringa, R., Activation or frustration of antitumor responses by T-cell-based immune modulation, Semin. Immunol., 9(5), 323, 1997.
343. Santiago-Schwarz, F., Positive and negative regulation of the myeloid dendritic cell lineage, J. Leukoc. Biol., 66(2), 209, 1999.
344. Mulders, P., Pang, S., Dannull, J., Kaboo, R., Hinkel, A., Michel, K., Tso, C.L., Roth, M., and Belldegrun, A., Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates, Cancer Res., 58(5), 956, 1998.
345. + T cells, J. Immunol., 158(4), 1749, 1997.
346. Eloranta, M.L, and Alm, G.V., Splenic marginal metallophilic macrophages and marginal zone macrophages are the major interferon-alpha/beta producers in mice upon intravenous challenge with herpes simplex virus, Scand. J. Immunol., 49(4), 391, 1999.
347. Seiler, P., Aichele, P., Odermatt, B., Hengartner, H., Zinkernagel, R.M., and Schwendener, R.A., Crucial role of marginal zone macrophages and marginal zone metallophils in the clearance of lymphocytic choriomeningitis virus infection, Eur. J. ImmunoL, 27(10), 2626, 1997.
348. Leenen, P.J., Radosevic, K., Voerman, J.S., Salomon, B., van Rooijen, N., Klatzmann, D., and van Ewijk, W., Heterogeneity of mouse spleen dendritic cells: In vivo phagocytic activity, expression of macrophage markers, arid subpopulation turnover, J. Immunol, 160(5), 2166, 1998.
349. Claassen, I.J., Osterhaus, A.D., and Claassen, E., Antigen detection in vivo after immunization with different presentation forms of rabies virus antigen: Involvement of marginal metallophilic macrophages in the uptake of immue-stimulating complexes, Eur. J. Immunol., 25(5), 1446, 1995.
350. Demoy, M., Andreux, J.-P., Weingarten, C., Gouritin, B., Guilloux, V., and Couvreur, P., In vitro evaluation of nanoparticles spleen capture, Life Sci., 64(15), 1329, 1999.
351. Linehan, S.A., Martinez-Pomares, L., Stahl, P.D., and Cordon, S., Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells, J. Exp. Med., 189(12), 1961, 1999.
352. 2-macroglobulin receptor/low density lipoprotein receptor-related protein in human tissues, Cell Tissue Res., 269(3), 375, 1992.
353. Chu, C.T. and Pizzo, S.V., Receptor-mediated antigen delivery in macrophages, J. Immunol., 150(1), 48, 1993.
354. 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A, J. Biol. Chem., 267, 12420, 1992.
355. Turing, T., Gambotto, A., Robbins, P.D., Storkus, W.J., and DeLeo, A.B., Codelivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization in mice: Studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen, Gene Ther., 6(4), 629, 1999.
356. Sampath, D., Castro, M., Look, D.C., and Holtzman, M.J., Constructive activation of an epithelial signal transducer and activator of transcription (STAT) pathway in asthma, J. Clin. Invest., 103(9), 1353, 1999.
357. Bregenholt, S. and Claesson, M.H., Increased intracellular Th1 cytokines in seid mice with inflammatory bowel disease, Eur. J. Immunol, 28(1), 379, 1998.
358. Mellado, M., Llorente, M., Rodriguez-Frade, J.M., Lusa, P., Martinez, A.C., and del Real, G., HIV-1 envelope protein gp120 triggers a Th2 response in mice shifts to Th1 in the presernce of human growth hormome, Vaccine, 16(11-12), 1111, 1998.
359. Chun, S., Daheshia, M., Lee, S., Eo, S.K., and Rouse, B.T., Distrubution fate and mechanism of immune modulation following mucosal delivery of plasmid DNA encoding IL-10, J. Immunol, 163(5), 2393, 1999.
360. Ishii, K.J., Weiss, W.R., Ichino, M., Verthelyi, D., and Klinman, D.M., Activity and safety of DNA plasmids encoding IL-4 and IFN gamma, Gene Ther., 6(2), 237-244, 1999.
361. Aichele, P., Brduscha-Riem, K., Zinkernagel, R.M., Hengartner, H., and Pircher, H., T cell priming versus T cell tolerance induced by synthetic peptides, J. Exp. Med., 182(1), 261, 1995.
362. Tan, J., Yang, N.S., Turner, J.G., Niu, G.L., Maassab, H.F., Sun, J., Herlocher, M.L., Chang, A.E., and Yu, H., Interleukin-12 cDNA skin transfection potentiates human papilloma virus E6 DNA vaccine-induced antitumor immune response, Cancer Gene Ther., 6(4), 331, 1999.
363. Cho, J.H., Lee, S.,W., and Sung, Y.C., Enhanced cellular immunity to hepatitis C virus nonstructural proteins by codelivery of granylocyte macrophage-colony stimulating factor gene in intramuscular DNA immunization, Vaccine, 17(9-10), 1136, 1999.
364. Goletz, T.J., Klimpel, K.R., Leppla, S.H., Keith, J.M., and Berzofsky, J.A., Delivery of antigens to the MHC class I pathway using bacterial toxins, Hum. Immunol, 54(2), 129, 1997.
365. Xin, K.Q., Hamajima, K., Sasaki, S., Tsuji, T., Watabe, S., Okada, E., and Okuda, K., IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine, Vaccine, 17(7-8), 858, 1999.
366. Lunde, E., Munthe, L.A., Vabo, A., Sandlie, I., and Bogen, B., Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells, Nat. Biotech., 17(7), 670, 1999.
367. Minev, B.R., Chavez, F.L., and Mitchell, M.S., Cancer vaccines: Novel approaches and new promise, Pharmacol. Ther., 81(2), 121, 1999.
368. Stevenson, F.K., Link, jr., C.J.,Traynor, A., Yu, H., and Corr, M., DNA vaccination against multiple myeloma, Semin. Hematol. 36(1 Suppl. 3), 38, 1999.
369. Zinkernagel, R.M., Ehl, S., Aichele, P., Oehen, S., Kundig, T., and Hengartner, H., Antigen localisation regulates immune responses in a dose-and time-dependent fashion: A geographical view of immune reactivity, Immunol Rev., 156, 199, 1997.
370. O'Connell, J., O'Sullivan, G.C., Collins, J.K., and Shanahan, F., The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand, J. Exp. Med., 184(3), 1075, 1996.
371. Nakashima, M., Sonoda, K., and Watanabe, T., Inhibition of cell growth and induction of apoptosis cell death by the human tumor-associated antigen RCAS1, Nat. Medicine, 5(8), 938, 1999.
372. Esche, C., Lokshin, A., Shurin, G.V., Gastman, B.R., Rabinowich, H., Watkins, S.C., Lotze, M.T., and Shurin, M.R., Tumor's other immune targets: Dendritic cells, J. Leukoc. Biol., 66(2), 336, 1999.
373. Chappell, D.B., Zaks, T.Z., Rosenberg, S.A., and Restifo, N.P., Human melanoma cells do not express Fas (Apo-1/CD95) ligand, Cancer Res., 59(1), 59, 1999.
374. Krammer, P.H., CD95(APO-1/Fas)-mediated apoptosis: Live and let die, Adv. Immunol., 71, 163, 1999.
375. Chackerian, B., Lowy, D.R., and Schiller, J.T., Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles, Proc. Natl. Acad. Sci. USA, 96(5), 2373, 1999.
376. De Bruijn, M.L., Greenstone, H.L., Vermeulen, H., Melief, C.J., Lowy, D.R., Schiller, J.T., and Kast, W.M., L1-specific protection from tumor challenge elicited by HPV16 virus-like particles, Virology, 250(2), 371, 1998.
377. Lee, P.P., Yee, C., Savage, P.A.L.F., Brockstedt, D., Weber, J.S., Johnson, D., Swetter, S., Thompson, J., Greengerg, P.D., Roederer, M., and Davis, M.M., Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat. Medicine, 5(6), 677, 1999.
378. Avigan, D., Dendritic cells: Development, function and potential use for cancer immunotherapy., Blood Rev., 13(1), 51, 1999.
379. Tarte, K. and Klein, B., Dendritic cell-based vaccine: A promising approach for cancer imimunotherapy, Leukemia, 13(5), 653, 1999.
380. Gabaglia, C.R., Pedersen, B., Hitt, M., Burdin, N., Sercarz, E.E., Graham, F.L., Gauldie, J., and Braciak, T.A., A single intramuscular injection with an adenovirus-expressing IL-12 protects BALB/c mice against Leishmania major infection, while treatment with an IL-4-expressing vector increases disease susceptibility in B10.D2 mice, J. Immunol., 162(2), 753, 1999.
381. Kielian, T., Nagai, E., Ikubo, A., Rasmussen, C.A., and Suzuki,T., Granulocyte/macrophagecolony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein 1alpha and accumulation of dendritic cells at vaccination sites in vivo, Cancer Immunol. Immunother., 48(2-3), 123, 1999.
382. Fernandez, N.C., Lozier, A., Flament, C., Ricciadri-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., and Zitvogel, L., Dendritic cells directly trigger NK cell function: Cross-talk revelevant in innate anti-tumor immune responses in vivo, Nat. Medicine, 5(4), 405, 1999.
383. Schweighoffer, T., Berger, M., Buschle, M., Schmidt, W., and Birnstiel, M.L., Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines, Cytokines Mol. Ther., 2(3), 185, 1996.
384. Schmidt, W., Maass, G., Buschle, M., Schweighoffer, T., Berger, M., Herbst, E., Schilcher, F., and Birnstiel, M.L., Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET), Gene, 190(1), 211, 1997.
385. Palmer, K., Moore, J., Everard, M., Rodgers, S., Rees, R.C., Murray, A.K., Mascari, R., Kirkwood, J., Riches, P.G., Fisher, C., Thomas, J.M., Harries, M., Johnston, S.R., Collins, M.K., and Gore, M.E., Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma, Hum. Gene Ther., 10(8), 1261, 1999.
386. Mulders, P., Tso, C.L., Pang, S., Kaboo, R., McBride, W.H., Hinkel, A., Gitlitz, B., Dannull, J., Figlin, R., and Belldegrun, A., Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma, J. Immunother., 21(3), 170, 1998.
387. Bendandi, M., Gocke, C.D., Korbin, C.B., Benko, F.A., Sternas, L.A., Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey, P.L., Jaffe, E.S., Creekmore, S.P., Longo, D.L., and Kwak, L.W., Complete molecular remissions induced by patient-specific vaccination plus granulocyte-macrophage colony-stimulating factor against lymphoma, Nat. Medicine, 5(10), 1171, 1999.
388. Hrouda, D., Perry, M., and Gfaldleish, A.G., Gene therapy for prostate cancer, Semin. Oncol., 26(4), 455, 1999.
389. Rosenberg, S.A., Zhai, Y., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M., Topalian, S.L., Restifo, N.P., Seipp, C.A., Einhorn, J.H., Roberts, B., and White, D.E., Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens, J. Natl. Cancer Inst., 90(24), 1894, 1998.
390. Rosenberg, S. A., Yang J.C., Schwartzentruber, D.J., Hwu, P., Marincola, F.M.,Topalian, S.L., Restifo, N.P., Sznol, M., Schwarz, S.L., Spiess, P.J., Wunderlich, J.R., Seipp, C.A., Einhorn, J.H., Rogers-Freezer, L., and White, D.E., Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine, J. Immunol., 163(3), 1690, 1999.
391. Irvine, K.R., McCabe, B.J., Rosenberg, S.A., and Restifo, N.P., Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL, J. Immunol, 154(9), 4651, 1995.
392. Irvine, K.R., Rao, J.B., Rosenberg, S.A., and Restifo, N.P., Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases, J. Immunol., 156(1), 238, 1996.
393. Irvine, K.R., Chamberlain, R.S., Shulman, E.P., Surman, D.R., Rosenberg, S.A., and Restifo, N.P., Enhanci ng efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors, J. Natl. Cancer Inst., 89(21), 1595, 1997.
394. Irvine, K.R., Chamberlain, R.S., Shulman, E.P., Rosenberg, S.A., and Restifo, N.P., Route of immunization and the therapeutic impact of recombinant anticancer vaccines, J. Natl. Cancer Inst., 89(5), 390, 1997.
395. Irvine, K.R., Parkhurst, M.R., Shulnan, E.P., Tupesis, J.P., Custer, M., Touloukian, C.E., Robbins, P.F., Yafal, A.G., Greenhalgh, P., Sutmuller, R.P., Offringa, R., Rosenberg, S.A., and Restifo, N.P., Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens, Cancer Res., 59(11), 2536, 1999.
396. Watanabe, M., Fenton, R.G., Wigginton, J.M., McCormick, K.L., Volker, K.M., Fogler, W.E., Roessler, P.G., and Wiltraout, R.H., Intradermal delivery of IL-12 naked DNA induces systemic NK cell activation and Th1 response in vivo that is independent of endogenous IL-12 production, J. Immunol, 163(4), 1943, 1999.
397. +) T lymphocytes, Proc. Natl. Acad. Sci. USA, 96(6), 2982, 1999.
398. Overwijk, W.W., Tsung, A., Irvine, K.R., Parkhurst, M.R., Goletz, T.J., Tsung, K., Carroll, M.W., Liu, C., Moss, B., Rosenberg, S.A., and Restifo, N.P., gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand, J. Exp. Med., 188(2), 277, 1998.
399. Chamberlain, R.S., Prospects for the therapeutic use of anticancer vaccines, Drugs, 57(3), 309, 1999.
400. Restifo, N.P. and Rosenberg, S.A., Developing recombinant and synthetic vaccines for the treatment of melanoma, Curr. Opin. Oncol., 11(1), 50, 1999.
401. Biragyn, A., Tani, K., Grimm, M.C., Weeks, S., and Kwak, L.W., Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity, Nat. Biotech., 17(3), 253, 1999.
402. Bellone, M., lezza, G., Imro, M.A., and Protti, M.P., Cancer immunotherapy: Synthetic and natural peptides in the balance, Immunol Today, 20(10), 457, 1999.
403. Ansardi, D.C., Moldoveanu, Z., Porter, D.C., Walker, D.E., Conry, R.M., LoBuglio, A.F., McPherson, S., and Morrow, C.D., Characterization of poliovirus replicons encoding carcinoembryonic antigen, Cancer Res., 54(24), 6359, 1994.
404. Smith, B.F., Baker, H.J., Curiel, D.T. Jiang, W., and Conry, R.M., Humoral and cellular immune responses of dogs immunized with a nucleic acid vaccine encoding human carcinoembryonic antigen, Gene Ther., 5(7), 865, 1998.
405. Toes, R.E., Hoebert, R.C., van der Veort, E.L., Ressing, M.E., van der Eb, A.J., Melief, C.J., and Offringa, R., Protective antitumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-pearls fashion, Proc. Natl. Acad. Sci. USA, 94(26), 14660, 1997.
406. Slovin, S.F. and Scher, H.I., Peptide and carbohydrate vaccines in relapsed prostate cancer: Immunogenicity of synthetic vaccines in man - clinical trials at Memorial Sloan-Kettering Cancer Center, Semin. Oncol., 26(4), 448, 1999.
407. Kensil, C.R., Wu, J.-Y., and Soltysik, S., Structural and immunological characterization of the vaccine adjuvant QS-21, in Vaccine Design: The Subunit and Adjuvant Approach, Vol. 6, 1st ed., Powell, M.F., Newman, M.J., and Burdman, J.R., Eds., New York: Plenum, 1995, 525.
408. Costello, R.T., Gastaut, J.-A., and Olive, D., What is the real role of CD40 in cancer immunotherapy?, Immunol. Today, 20(11), 488-493, 1999.
409. Erb, K.J., Atopic disorders: A default pathway in the absence of infection?, Immunol. Today, 20(7), 317, 1999.
410. Zhang, H.-G., Liu, D., Heike, Y., Yang, P., Wang, Z., Wang, X., Curiel, D.T., Zhou, T., and Mountz, J.D., Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells, Nat. Biotech., 16(11), 1045, 1998.
411. Matsue, H., Matsue, K., Walters, M., Okumura, K., Yagita, H., and Takashima, A., Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells, Nat. Medicine, 5(8), 930, 1999.
412. Dutton, R. W., Swain, S.L., and Bradley, L.M., The generation and maintenance of memory T and B cells, Immunol. Today, 20(7), 291,1999.
413. Stevenson, F.K. and Natvig, J., Autoantibodies revealed: The role of B cells in autoimmune disease, Immunol. Today, 20(7), 296, 1999.
414. van Neerven, R.J., The role of allergen-specific T cells in the allergic immune response: Relevance to allergy vaccination, Allergy, 54(6), 5521, 1999.
415. Falcioni, F., Ito, K., Vidovic, D., Belunis, C., Campbell, R., Berthel, S.J., Bolin, D.R., Gillespie, P.B., Huby, N., Oison, G.L., Sarabu, R., Guenot, J., Madison, V., Hammer, J., Sinigaglia, F., Steinmetz, M., and Nagy, Z.A., Peptidomimetic compounds that inhibit antigen presentation by autoimmune disease-associated class II major histocompatibility molecules, Nat. Biotech., 17(6), 562, 1999.
416. Sigal, L.J., Reiser, H., and Rock, K.L., The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo, J. Immunol., 161(6), 2740, 1998.
417. Weiner, H.L. and van Rees, E.P., Mucosal tolerance., Immunol Lett., 69(1), 3, 1999.
418. +) T cells, J. Exp. Med., 188(4), 651, 1998.
419. Gimmi, C.D., Freeman, G.J., Gribben, J.G., Gray, G., and Nadler, L.M., Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation, Proc. Natl. Acad. Sci. USA, 90(14), 6586, 1993.
420. Goodnow, C.C., Balancing immunity and tolerance: Deleting and tuning lymphocyte repertoires, Proc. Natl. Acad. Sci. USA, 93(6), 2264, 1996.
421. Kapsenberg, M.L. and Kalinski, P., The concept of type 1 and type 2 antigen-presenting cells, Immunol. Lett., 69(1), 5, 1999.
422. Marth, T., Zeitz, M., Ludviksson, B.R., Strober, W., and Kelsall, B.L., Extinction of IL-12 signaling promotes Fas-mediated apoptosis of antigen-specific T cells, J. Immunol. 162(12), 7233, 1999.
423. Karp, C.L., Biron, C.A., and Irani, D.N., Interferon ß in multiple sclerosis: is IL-12 suppression the key?, Immunol. Today, 21(1), 24, 2000.
424. Boccaccio, G.L., Mor, F., and Steinman, L., Non-coding plasmid DNA induces IFN-gamma in vivo and supresses autoimmune encephalomyelitis, Int. Immunol., 11(2), 289, 1999.
425. Dalum, I., Butler, D.M., Jensen, M.R., Hindersson, P., Steinaa, L., Eaterson, A.M., Grell, S.N., Feldmann, M., Elsner, H.I., and Mouritsen, S., Therapeutic antibodies elicited by immunization against TNF-α, Nat. Biotech., 17(7), 666, 1999.
426. Strobel, S. and Mowat, A.M., Immune responses to dietary antigens: Oral tolerance, Immunol. Today, 19(4), 173, 1998.
427. Coon, B., An, L.L., Whitton, J.L., and von Herrath, M.G., DNA immunization to prevent autoimmune diabetes, J. Clin. Invest., 194(2), 189, 1999.
428. Fowler, E. and Weiner, H.L., Oral tolerance: Elucidation of mechanisms and application to treatment ol autoimmune diseases, Biopolymers, 43(4), 323, 1997.
429. Bischoff, S.C., The gut as target organ for oral immunovaccination with allergen DNA: New hope for patients with anaphylactic reactions to food?, Gut, 45(1), 11, 1999.
430. Rizzo, L.V., Miller-Rivero, N.E., Chan, C.-C., Wiggert, B., Nussenblatt, R.B., and Caspi, R.R., lriterleukin-2 treatment potentiates induction of oral tolerance in a murine model ol autoimmunity, J. Clin. Invest., 94(4), 1668, 1994.
431. Kaiserlain, D. and Etchart, N., Entry sites for oral vaccines and drugs: A role for M cells, enterocytes and dendritic cells?, Semin. Immunol, 11 (3), 217, 1999.
432. Roy, K., Mao, H.Q., Huang, S.K., and Leong, K.W., Oral gene delivery with chitosan - DNA nanoparticles generates immunological protection in a murine model of peanut allergy, Nat. Medicine, 5(4), 387, 1999.
433. Mor, T.S., Gomez-Lim, M.A., and Palmer, K.E., Perspective: Edible vaccines - A concept coming of age, Trends Microbiol., 6(11), 449, 1998.
434. Ruiz, P.J., Wolkowicz, R., Waisman, A., Hirschberg, D.L., Carmi, P., Erez, N., Garren, H., Herkel, J., Karpuj, M., Steinman, L., Rotter, V., and Cohen, I.R., Idiotypic immunization induces immunity to mutated p53 and tumor rejection, Nat. Medicine, 4(6), 710, 1998.
435. Ma, J., Samuel, J., Kwon, G.S., Noujaim, A.A., and Madiyalakan, R., Induction of antiidiotypic humoral and cellular immune responses by a murine monoclonal antibody recognizing the ovarian carcinoma antigen CA125 encapsulated in biodegradable microspheres, Cancer Immunol. Immunother., 47(1), 13, 1998.
436. Kwak, L.W., Theilemans, K., and Massaia, M., Idiotypic vaccination as therapy for multiple myeloma, Semin. Hematol., 36(1 Suppl. 3), 34, 1999.
437. Lim, S.H. and Bailey-Wood, R., Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma, Int. J. Cancer, 83(2), 215, 1999.
438. Mellstedt, H. and Osterberg, A., Active idiotype vaccination in multiple myeloma. CM-CSF may be an important adjuvant cytokine, Pathol. Biol., 47(2), 211, 1999.
439. Syrengelas, A.D. and Levy, R., DNA vaccination against the idiotype of a murine B cell lymphoma: Mechanism of tumor protection, J. Immunol., 162(8), 4790, 1999.
440. Kwak, L.W., Tumor vaccination strategies combined with autologues peripheral stem cell transplantation, Ann. Oncol, 9(Suppl. 1), S41, 1998.
441. Bloom, B.R. and Widdus, R., Vaccine visions and their global impact, Nat. Medicine, 4(5), 480, 1998.
442. Peltola, H., Prophylaxis of bacterial memingitis, Infect. Dis. Clin. North Am., 13(3), 685, 1999.
443. Batson, A., Sustainable introduction of affordable new vaccines: The targeting strategy, Vaccine, 16(Suppl), 893, 1998.
444. Mahoney, R.T. and Maynard, J.E., The introduction of new vaccines into developing countries, Vaccine, 17(7-8), 646, 1999.
445. Batson, A., Win-win interactions between the public and private sectors, Nat. Medicine, 4(5), 487, 1998.
446. Ridgway, D., No-fault vaccine insurance: Lessons from the national vaccine injury compensation program, J. Health Polit. Policy Law, 24(1), 59, 1999.
447. Saldarini, R.J., For vaccines, the future is now, Nat. Medicine, 4(5), 485, 1998.